Abstract
The peptidomimetic hydroxamate metalloproteinase inhibitor batimastat (BB-94) was assessed for its ability to neutralize the systemic effects (lethality, hemorrhage and coagulopathy) induced by the venom of Bothrops asper, the most important snake
from a medical standpoint in Central America. Batimastat inhibited lethality when a venom challenge dose of two LD50s was
used by intraperitoneal and intravenous routes, with ED50s of 250 and 22 mM, respectively